EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer

Sun Min Lim iD, Stefanie S Schalm, Eun Ji Lee iD, Sewon Park, Chiara Conti, Yves A Millet, Rich Woessner, Zhuo Zhang, Luz E Tavera-Mendoza, Faith Stevison, Faris Albayya, Thomas A Dineen und 8 weitere

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241280689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 21.10.2024. Verfasst von Sun Min Lim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Blueprint Medicines Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), most patients with non-small-cell lung cancer (NSCLC) eventually develop resistance to these agents. Notably, EGFR_C797S mutations confer resistance to the third-generation EGFR-TKI osimertinib and no approved post-osimertinib targeted pharmacology options are currently available. BLU-945 is a novel, reversible, and orally available next-generation EGFR-TKI that selectively targets EGFR-activating ( EGFRm) and resistance mutations (including EGFR_C797S) with nanomolar potency while sparing wild-type EGFR in vitro.

Methods

In vitro activity of BLU-945 as a single agent and in combination with osimertinib was tested in engineered EGFR-mutant cell lines as well as patient-derived cells and patient-derived organoids. In vivo activity was evaluated in osimertinib-resistant patient-derived xenograft mouse models. Three patient cases from the global, first-in-human, phase I/II SYMPHONY trial (NCT04862780) demonstrating the clinical efficacy of BLU-945 were reported.

Results

In vitro BLU-945 demonstrated inhibited cell viability and growth of EGFR-mutant/osimertinib-resistant cell lines. BLU-945 demonstrated in vivo tumor shrinkage in osimertinib-resistant models of NSCLC (osimertinib second line: EGFR_L858R/C797S and third line: EGFR_ex19del/T790M/C797S and L858R/T790M/C797S) both as monotherapy and in combination with osimertinib. BLU-945 also demonstrated tumor shrinkage in patients from the SYMPHONY trial.

Conclusion

Our findings demonstrate the preclinical and early clinical activity of BLU-945 in EGFRm NSCLC progressing on previous EGFR-TKIs.

Schlagwörter

Stichwörter der Autor:innen

BLU-945EGFREGFR inhibitorsNSCLCTKIclinical trial designdrug resistanceosimertinibpatient-derived xenograft

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Blueprint Medicines Corporation, Cambridge, MA, USA.
  • Department of Biomedical Science Institute, Graduated School of Medical Science, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • JEUK Institute for Cancer Research, JEUK Co. Ltd., Seoul, Republic of Korea.
  • Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

ORCID-Profile: Sun Min Lim, Eun Ji Lee, Byoung Chul Cho

Förderung

  • Blueprint Medicines Corporation

Zitieren

APA

Lim, S. M., Schalm, S. S., Lee, E. J., Park, S., Conti, C., Millet, Y. A., Woessner, R., Zhang, Z., Tavera-Mendoza, L. E., Stevison, F., Albayya, F., Dineen, T. A., Hsieh, J., Oh, S. Y., Zalutskaya, A., Rotow, J., Goto, K., Lee, D. H., Yun, M. R., & Cho, B. C. (2024). BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241280689

Vancouver

Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, et al. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241280689

BibTeX
@article{Lim2024,
  author = {Lim, Sun Min and Schalm, Stefanie S and Lee, Eun Ji and Park, Sewon and Conti, Chiara and Millet, Yves A and Woessner, Rich and Zhang, Zhuo and Tavera-Mendoza, Luz E and Stevison, Faith and Albayya, Faris and Dineen, Thomas A and Hsieh, John and Oh, Seung Yeon and Zalutskaya, Alena and Rotow, Julia and Goto, Koichi and Lee, Dae-Ho and Yun, Mi Ran and Cho, Byoung Chul},
  title = {BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241280689}
}
Kostenlos starten →